Researchers at the Francis Crick Institute and the Latvian Institute of Organic Synthesis have designed a drug-like compound which effectively blocks a critical step in the malaria parasite life cycle and are working to develop this compound into a potential first of its kind malaria treatment. While drugs and mosquito… Read More
The latest episode of the free DDW podcast is out, “Precision medicine in the era of artificial intelligence”. It covers one narrated article of the same title written for DDW and read aloud by Megan Thomas. It was written by Dr Lofti Chouchane and Dr Javaid Sheikh. Dr Chouchane is… Read More
This is the latest episode of the free DDW podcast, “Precision medicine in the era of artificial intelligence”. It covers one narrated article of the same title written for DDW and read aloud by Megan Thomas. It was written by Dr Lofti Chouchane and Dr Javaid Sheikh, who discuss the value… Read More
By Mette Lauritzen PhD, Product Marketing Manager, Nuclear Molecular Imaging, Bruker BioSpin Different types of tumours, and their varying reactions to treatment, make the search for new effective cancer therapies incredibly challenging. Preclinical in vivo imaging methods are helping to obtain further knowledge of tumour morphology, progression, and biomarker expression… Read More
Lu Rahman takes look at some of the latest imaging innovation available and how it can benefit drug target identification and drug discovery research. Imaging is an important element within the drug discovery and development process providing researchers with information that can help identify potential drug targets or see how… Read More
On May 27, 2021, ELRIG’s “hot topic” webinar, Weathering the Storm: Drug Discovery & the ELRIG Community takes place virtually. Scientists, medical professionals, business leaders and others associated with the life sciences, which ELRIG consider to be the core of their drug discovery community, and who, throughout the pandemic, have… Read More
Scientists have successfully treated flies displaying behavioural problems linked to newly discovered schizophrenia-associated genes in humans, using common anti-psychotics. Schizophrenia is a severe long-term mental health condition that is historically poorly understood and treated. It is relatively common, affecting 1-2% of the population, and is known to be up to… Read More
HelaPlex is working with Scispot to create a digital life science accelerator. The collaboration will allow HelaPlex to offer a secure digital space to its members and enable them to manage research, resources, and partners in one spot, as per commercial regulatory requirements. “I believe the bio revolution is on… Read More
According to GlobalData, the diabetes market has gone through significant maturation, attributed to increased innovation and modernisation of therapeutic treatments over the past 20 years. The market has been a lucrative space for drug developers, as the disease is highly prevalent and patient numbers are expected to continue increasing in… Read More
BlueRock Therapeutics, FUJIFILM Cellular Dynamics and Opsis Therapeutics have entered a strategic research joint venture focused on developing cell therapies for patients with ocular diseases. The companies will combine their collective expertise to discover and develop off-the-shelf iPS cell therapies for ocular diseases. Under this agreement, BlueRock Therapeutics will have… Read More
Medicago and GlaxoSmithKline (GSK) have reported positive interim Phase II clinical trial safety and immunogenicity data for Medicago’s plant-derived Covid-19 vaccine candidate, which has been tested in combination with GSK’s pandemic adjuvant. These results are part of the ongoing Phase II/III study and reiterate the promising profile observed during Phase… Read More
Genomic sequencing service provider Macrogen Europe has achieved an upgrade to its next generation sequencing (NGS) capacity. The installation of an additional Illumina NovaSeq 6000 high-throughput sequencing system in its headquarters in the Netherlands helps manage increased demand with high-quality results and fast, reliable turnaround times. The addition of the… Read More
Charles River has signed a definitive agreement to acquire Vigene Biosciences. The purchase price is expected to be US$292.5 million, subject to customary closing adjustments. The acquisition will enhance Charles River’s gene therapy capabilities in the high-growth, value-added cell and gene therapy CDMO sector. In addition to the initial purchase… Read More
Sphere Fluidics has enhanced the capability and performance of its Cyto-Mine System. This is an automated platform which integrates single cell screening, sorting, dispensing, imaging and clone verification. The simplified design should help streamline workflows, reduce costs, increase throughput, and enable high-value clones to be captured in a single run. Read More
Nearly half of pharmaceutical companies (48%) admit their competitiveness suffers because they cannot extract or use insights from data they already have within their business. An equal percentage (48%) admit they do not use their own data for business decisions as well as they could. The findings are from research… Read More
Listen to this article on the DDW Podcast: Now a key pillar in the early stages of therapeutics development, the limitations of introducing a DNA double strand break mean that workflows are broadening away from CRISPR–Cas as a gene knockout technology and towards platforms that enable genetic modulation and… Read More
